European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

ALGAE4IBD –FROM NATURE TO BEDSIDE- ALGAE BASED BIO COMPOUND FOR PREVENTION AND TREATMENT OF INFLAMMATION, PAIN AND IBD

Descripción del proyecto

DE EN ES FR IT PL

Sumergirse en las profundidades para encontrar algas antiinflamatorias

¿Y si la solución a las enfermedades crónicas estuviera en los océanos, los ríos o los lagos? El proyecto Algae4IBD, financiado con fondos europeos, responderá a esta pregunta. Mediante el estudio de compuestos procedentes de microalgas y macroalgas marinas y de agua dulce desde el laboratorio hasta su comercialización, el proyecto investigará exhaustivamente los medios para transformar recursos biológicos, naturales y acuáticos en principios activos desde el punto de vista biológico para la prevención y el tratamiento de la enfermedad inflamatoria intestinal (EII). En concreto, desarrollará compuestos a base de algas, a la vez que garantizará la conservación de la biodiversidad algal mediante tecnologías pioneras de extracción y cultivo. Algae4IBD propone soluciones innovadoras para utilizar productos a base de algas de forma sostenible con una mayor calidad nutricional, a fin de tener un efecto positivo en los enfermos de EII.

Objetivo

Algae4IBD's mission is to develop commercial products for Inflammatory Bowel Disease (IBD) prevention and treatment using aquatic natural biological resources. With the emerging developments in natural product, notable success has been achieved in discovering natural products and their synthetic structural analogues with anti-inflammatory activity. However, global biodiversity remains a largely unexploited resource for natural bioactive molecules with an enormous potential for developing commercial products with public health benefits. Micro and macroalgae, found in marine and freshwater, have been identified as promising sources of bioactive compounds including small molecules and secondary metabolites with a wide range of bioactivities as an antioxidant, anti-inflammatory and cancer preventive. Consumption of algae could, therefore, provide defence against chronic inflammatory diseases such as IBD, that until date have no effective cure. This project offers nature to bedside approach, using an entire development along the value chain for a new biodiscovery therapeutic approach by developing and examining algae-based compounds for IBD patients while guaranteeing algae's biodiversity preservation. We propose innovative solutions for increasing the use of algae-based ingredients and to ensure the science-based improvement of nutritional quality and its effect on public health. The researchers, companies and hospitals involved in the different stages of the project will use the biodiversity of algae, both micro and macro, as a wide source for bioactive compounds using state-of-the-art cultivation and extraction technologies for obtaining sufficient amounts of the bio-active molecules together with novel processing protocols. It will result in novel algal-based, high-quality bioactive compounds at GMP grade and lower costs for dual purposes – IBD prevention and treatment in relevance to the food as well as the pharmaceutical industries.

Ámbito científico

Palabras clave

Programa(s)

Tema(s)

Convocatoria de propuestas

H2020-FNR-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-FNR-2020-2

Régimen de financiación

RIA - Research and Innovation action

Coordinador

MIGAL GALILEE RESEARCH INSTITUTE LTD
Aportación neta de la UEn
€ 895 219,74
Dirección
SOUTH INDUSTRIAL ZONE
11016 KIRYAT SHEMONA
Israel

Ver en el mapa
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 895 222,50

Participantes (23)

Compartir esta página

Descargar

Última actualización: 28 Diciembre 2023

Mi folleto

Permalink: https://cordis.europa.eu/project/id/101000501/es

European Union, 2024